Is It Time to Rethink Standard Anticoagulation? Apixaban vs VKA in HeartMate 3 LVADs
Tania Ahuja, Clinical Assistant Professor, Assistant Director of Clinical Pharmacy and Clinical Pharmacotherapy Specialist, shared a post on X:
”Is it time to re-think anticoagulation for HeartMate3 (HM3) LVADs?
2 RCTs and 3 observational studies including 209 patients: 119 in the apixaban group and 90 in the VKA group demonstrating apixaban just as good as VKA and with less.”
Read the full article here.
Title: Efficacy and safety of apixaban versus vitamin K antagonists in patients with heartmate 3 fully magnetically levitated left ventricular assist device: a comprehensive meta-analysis
Authors: Andrea Tripoli, Miguel A. Samaniego, Norma N. Gamarra-Valverde, Shivraj Paneer Selvam, Edgardo Kaplinsky, Alejandro Barbagelata, Anna Mara Scandroglio, Juliana Giorgi
Stay updated on all science in the field of hematology with Hemostasis Today.
-
Jul 2, 2026, 16:13William Aird: When Deciding whether an Adult Patient is Anemic, Which Do You Usually Use?
-
Jul 2, 2026, 16:08Supporting Bleeding Disorders Community and Celebrating ASPEH Milestone – WFH
-
Jul 2, 2026, 15:59Raul Santos: Why Does LDL-C Remain Elevated in Many Patients?
-
Jul 2, 2026, 15:16Tim Patel: How Regular Movement Helps Keep Blood Flowing Throughout the Day
-
Jul 2, 2026, 13:16Nathan Connell: Is It Time to Rethink What We Tell Hemophilia B Carriers About Pregnancy?
-
Jul 2, 2026, 13:09Bruce Ovbiagele: WSO SCDKIDS Task Force’s Webinar Sheds Light On Care of Sickle Cell Disease-Related Stroke
-
Jul 2, 2026, 12:55Taraneh G. Farazi: The Latest Stroke Clinician Issue Highlights the Importance of Patient Voices in Dysphagia Care
-
Jul 2, 2026, 12:45Kaveh Mehrvar: The Gut–Brain Axis May Hold New Clues to Stroke Pathophysiology
-
Jul 2, 2026, 12:28Expanding Stroke Education Through Mobile Stroke Clinics – Ethiopia Stroke Foundation